Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer Leading to 60 Months Overall Survival: A Case Report
Small-cell lung cancer (SCLC) remains a disease with poor prognosis, particularly in extensive-stage SCLC (ES-SCLC). Current standard-of-care treatment includes chemotherapy with platinum agents and etoposide plus immunotherapy with atezolizumab or durvalumab, which has achieved a mean overall survi...
Gardado en:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
MDPI AG
2024-06-01
|
| Series: | Current Oncology |
| Assuntos: | |
| Acceso en liña: | https://www.mdpi.com/1718-7729/31/7/271 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|